FIELD: medicine.SUBSTANCE: invention relates to a compound of general formula (I) wherein the Cy1 cycle is phenyl, cyclohexyl, pyridinyl, pyrazolyl, triazolyl, thienyl, tetrahydrofuranyl； Cy2 cycle is a pyridine ring, a pyrimidine ring, a pyrazolopyrimidine ring, an imidazopyridazine ring, an imidazopyridine ring, a pyrrolopyridine ring, an imidazopyrazine ring or a pyrazolopyridine ring； R1 represents a halogen； C1-6-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen and (ii) hydroxy or C2-6-alkynyl group； phenyl optionally substituted with one or two R5 groups or indanyl； A 5-6 membered monocyclic heterocycle optionally substituted with one or two R5 groups or dihydrobenzofuran； -S(O)m1-R6； -SO2NR7R8； -OR14； R5 represents a halogen； cyano group； or C1-3-alkyl group optionally substituted with 1 to 3 substituents selected from the group consisting of (i) halogen, (ii) hydroxy groups and (iii) oxo groups； when there are two groups R5, the group R5 independently may be the same or different； R6, R7, R8, R14 or R20 respectively and independently represent (1) a hydrogen atom or (2) C1-6-alkyl group optionally substituted by (ii) a hydroxy group； R2 represents a halogen； C1-6-alkyl group optionally substituted with (i) a halogen or (ii) a hydroxy group； C3-6-cycloalkyl group； C1-6-alkoxy group； -NR28R29； pyrrolidinyl, azetidinyl； or -O-(oxetanyl)； R28 and R29 respectively and independently represent a hydrogen atom or C1-6-alkyl group optionally substituted by (ii) a hydroxy group； A1 and A2 respectively and are independently =CR3- or =N-； A3, A4, A5 and A6 respectively and are independently =CR4-； R3 and R4 respectively and independently represent a hydrogen atom； m1 is an integer from 0 to 2； p is an integer from 0 to 4； q is an integer from 0 to 2； r represents 0； provided that when p, q and r are respectively an integer of 2 or more, group R1, R2 and R3 respectively, and independently may be the same or dif
